(Medical Xpress)—An investigational drug that targets the immune system's ability to fight cancer is showing promising results in Yale Cancer Center (YCC) patients with a variety of advanced or metastatic forms of the disease. ...
Jun 4, 2013
0
0
Lung cancer patients given amrubicin (Calsed) as a second-line therapy had a significantly improved response rate and longer progression-free survival than patients treated with topotecan (Hycamtin), according to research ...
Jul 7, 2011
0
0
Asian non-small cell lung cancer (NSCLC) patients survive longer than Caucasians no matter how many drugs are given in a first-line setting, and the effect was apparent both before and after the introduction of targeted therapies ...
Jun 1, 2011
0
0
Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by multiple myeloma. The findings are published in Nature Medicine.
Mar 8, 2017
0
2
Once it has spread, uveal (intraocular or eye) melanoma—an unusual form of cancer—has a very high mortality rate. In a study published in Nature Communications, researchers and doctors at the University of Gothenburg ...
Aug 27, 2021
0
447
Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer ...
Feb 20, 2015
0
18
Nearly half of the 700,000 cancer patients who undergo surgical removal of a primary tumor each year suffer a recurrence of their disease at some point, and many of those patients will eventually die from their disease. The ...
Dec 27, 2012
1
0
A new Johns Hopkins study offers promise towards someday being able to non-invasively examine changes in cancerous tumors to determine whether they'll respond to radiation treatment, before treatment even begins.
Feb 28, 2019
0
4
(Medical Xpress)—Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. ...
Dec 24, 2012
0
0
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a ...
Jun 2, 2013
0
0
